Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... In today,s fast changing healthcare environment, ... positive health outcomes, improve profitability and enhance their ... in their communities. At ThoughtSpot 2015, Good ... announced a new set of innovative capabilities that ... help independent pharmacies endure the industry,s most pressing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 ... insights on the global resorcinol industry. The report highlights the various growth prospects ... scenarios and analysis of primary and secondary inputs from the existing players of ...
(Date:7/31/2015)... , July 31, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has filed ... Securities and Exchange Commission. The filed Form 20-F includes ... 31, 2015. The Form 20-F can be accessed by ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that ... be held at 10 a.m. EDT on Tuesday, June ... Terrence Donnelly Centre for Cellular and Biomolecular Research, University ... record date for the meeting is May 2, 2012. ...
... existence to a pair of information-carrying molecules: DNA and ... for life: they display hereditymeaning they can encode and ... time, through processes of Darwinian evolution. A ... performed by molecules other than DNA and RNA. ...
... They won,t be coming soon to a multiplex near ... at the atomic-scale in real-time have blockbuster potential. A ... (Berkeley Lab) and the University of California (UC) Berkeley ... between layers of graphene so that chemical reactions in ...
Cached Biology Technology:Generex Announces Date of Annual Stockholders' Meeting 2Generex Announces Date of Annual Stockholders' Meeting 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 2Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 4First atomic-scale real-time movies of platinum nanocrystal growth in liquids 2First atomic-scale real-time movies of platinum nanocrystal growth in liquids 3First atomic-scale real-time movies of platinum nanocrystal growth in liquids 4First atomic-scale real-time movies of platinum nanocrystal growth in liquids 5
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... new way to study the role of a critical ... schizophrenia, and alcohol addiction has been developed by a ... professor of biology at Penn State University. The new ... structure through which a nerve cell send signals to ...
... display or a solar panel, any conductive overlay had better ... oxide (ITO) for the job, but a high-tech material,s properties ... cheap and easy to manufacture as possible. In a new ... best-ever transparency and conductivity performance for an ITO made using ...
... 2012The global market value of Alzheimer,s disease therapeutics could soar ... actually change the course of the disease, reports Genetic ... is valued at $3 to $4 billion, shared among drugs ... do not alter the underlying disease, according to a ...
Cached Biology News:New model synapse could shed light on disorders such as epilepsy and anxiety 2New model synapse could shed light on disorders such as epilepsy and anxiety 3Chemists advance clear conductive thin films 2GEN reports on recent progress in Alzheimer's research 2
... the things youll be telling others after you ... Erica Golemis, One look at the table of ... in protein interaction will tell you immediately that ... part of your personal protein chemistry library. You ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... capillary electrophoresis, real-time PCR assays and bandshift ...
... Environment 2) Dot plot, Contour plot, ... Compensation 4) Cell Cycle 5) ... Intelligent batch generation of graphs and statistics ... drag-and-drop operations to perform complex batch analyses ...
Synonym: modified Grace's Insect medium...
Biology Products: